Diadexus, Inc. Stock

Equities

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Diadexus, Inc. -.--% -.--%
Sales 2014 26.11M 35.69M Sales 2015 17.88M 24.45M Capitalization 8.57M 11.71M
Net income 2014 -8M -10.94M Net income 2015 -7M -9.57M EV / Sales 2014 1.05 x
Net cash position 2014 198K 271K Net Debt 2015 5.24M 7.16M EV / Sales 2015 0.77 x
P/E ratio 2014
-3.26 x
P/E ratio 2015
-1.14 x
Employees -
Yield 2014 *
-
Yield 2015
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Investor Relations Contact - -
Members of the board TitleAgeSince
Director/Board Member 64 10-11-03
Director/Board Member 57 15-01-06
More insiders
Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.
More about the company